Education
About Us
Working with TipRanks
Follow Us
Clinical Laserthermia Systems AB Class B (SE:CLS.B)
:CLS.B
RESEARCH TOOLSreports
Top Page
Clinical Laserthermia Systems AB Class B
(Frankfurt:CLS.B)
34Underperform
Clinical Laserthermia Systems AB Class B (CLS.B) vs. S&P 500 (SPY)
Market Cap
kr59.49M
Dividend YieldN/A
Average Volume (3M)68.52K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth127.04%
EPS Growth92.31%
CountrySE
Employees17
SectorHealthcare
Sector Strength53
IndustryMedical - Devices
Share Statistics
EPS (TTM)-3.06
Shares Outstanding20,163,593
10 Day Avg. Volume68,838
30 Day Avg. Volume68,524
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model
Company DescriptionClinical Laserthermia Systems AB Class B (CLS.B) is a Swedish company specializing in the development and commercialization of advanced laser-based medical technologies. The company's core focus is on delivering innovative thermal treatment solutions for cancer care. Its flagship product, TRANBERG® Thermal Therapy System, is designed to provide precision thermal ablation therapies, which can be used in conjunction with other cancer treatments such as immunotherapy. CLS.B operates primarily in the medical devices and healthcare sectors, aiming to improve patient outcomes through minimally invasive procedures.
How the Company Makes MoneyClinical Laserthermia Systems AB generates revenue primarily through the sale and distribution of its TRANBERG® Thermal Therapy System and related consumables. The company targets healthcare providers, hospitals, and clinics that are involved in oncological treatments as its main customer base. Revenue is also derived from providing training and support services to ensure effective implementation and usage of its technology. Additionally, CLS.B may engage in strategic partnerships and collaborations with research institutions and other medical device companies to expand its market reach and enhance product offerings, thereby contributing to its earnings.
Clinical Laserthermia Systems AB Class B Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 18.78M | 8.27M | 6.27M | 2.25M | 1.33M | Gross Profit |
| 10.42M | 3.00M | -2.79M | -3.63M | 876.00K | EBIT |
| -54.25M | -65.93M | -67.44M | -60.68M | -51.81M | EBITDA |
| -44.76M | -68.41M | -57.84M | -57.05M | -51.61M | Net Income Common Stockholders |
| -47.62M | -79.79M | -70.66M | -63.62M | -57.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 22.51M | 15.33M | 10.59M | 31.17M | 11.87M | Total Assets |
| 78.56M | 57.73M | 49.51M | 66.74M | 44.40M | Total Debt |
| 224.00K | 454.00K | 30.68M | 273.50K | 673.50K | Net Debt |
| -22.28M | -14.88M | 20.23M | -1.43M | 78.83K | Total Liabilities |
| 12.88M | 14.20M | 41.64M | 45.55M | 30.47M | Stockholders Equity |
| 68.72M | 45.77M | 9.22M | 21.79M | 13.93M |
| Cash Flow | Free Cash Flow | |||
| -63.92M | -71.95M | -71.25M | -66.73M | -55.76M | Operating Cash Flow |
| 0.00 | -66.45M | -70.69M | -66.17M | -55.41M | Investing Cash Flow |
| -7.47M | -5.50M | -886.00K | -408.00K | -508.00K | Financing Cash Flow |
| 71.10M | 76.69M | 61.84M | 85.88M | 62.02M |
Clinical Laserthermia Systems AB Class B Technical Analysis
Neutral
2.95
Price Trends
3.08
Negative
3.42
Negative
4.24
Negative
Market Momentum
>-0.01
Negative
50.75
Neutral
40.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Neutral. The current price of 2.95 is above the 20-day moving average (MA) of 2.91, below the 50-day MA of 3.08, and below the 200-day MA of 4.24, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.75 is Neutral, neither overbought nor oversold. The STOCH value of 40.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CLS.B.
Clinical Laserthermia Systems AB Class B Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | kr9.96M | ― | ― | 96.10% | 94.79% | ||
52 Neutral | $5.23B | 3.70 | -41.86% | 2.84% | 16.58% | -0.16% | |
37 Underperform | kr84.52M | ― | -51.52% | ― | 955.20% | 47.31% | |
34 Underperform | kr59.49M | ― | -82.35% | ― | 127.04% | 92.31% | |
33 Underperform | kr27.52M | ― | ― | -63.52% | 93.00% | ||
28 Underperform | kr77.41M | ― | -19.16% | ― | ― | -13.59% |
* Healthcare Sector Average
Performance Comparison
SE:CLS.B
Clinical Laserthermia Systems AB Class B
2.95
-11.84
-80.05%
SE:LXB
Luxbright AB
0.74
-0.26
-26.37%
SE:QLIFE
Qlife Holding AB
2.20
0.84
62.12%
SE:S2M
S2Medical AB Class B
0.01
-0.02
-69.44%
SE:SPEC
SpectraCure AB
0.83
-2.16
-72.24%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.